| Ticker Details |
Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care. Its drug candidates are PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357.
|
| IPO Date: |
April 20, 2012 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$476.97M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.30 | 3.51%
|
| Avg Daily Range (30 D): |
$0.25 | 2.96%
|
| Avg Daily Range (90 D): |
$0.20 | 2.49%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.59M |
| Avg Daily Volume (30 D): |
.24M |
| Avg Daily Volume (90 D): |
.22M |
| Trade Size |
| Avg Trade Size (Sh.): |
116 |
| Avg Trade Size (Sh.) (30 D): |
58 |
| Avg Trade Size (Sh.) (90 D): |
57 |
| Institutional Trades |
| Total Institutional Trades: |
3,716 |
| Avg Institutional Trade: |
$2.05M |
| Avg Institutional Trade (30 D): |
$.62M |
| Avg Institutional Trade (90 D): |
$.96M |
| Avg Institutional Trade Volume: |
.05M |
| Avg Institutional Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.61M |
| Avg Closing Trade (30 D): |
$.63M |
| Avg Closing Trade (90 D): |
$1.03M |
| Avg Closing Volume: |
77.92K |
|
|
| Financials |
| |
TTM |
Q2 2026 |
Q1 2026 |
|
Basic EPS
|
$.54
|
$.16
|
$-.07
|
|
Diluted EPS
|
$.52
|
$.16
|
$-.07
|
|
Revenue
|
$231.24M
|
$56.5M
|
$44.81M
|
|
Gross Profit
|
$173.05M
|
$44.03M
|
$34.39M
|
|
Net Income / Loss
|
$26.72M
|
$8.19M
|
$-3.75M
|
|
Operating Income / Loss
|
$30.44M
|
$7.59M
|
$-3.83M
|
|
Cost of Revenue
|
$58.2M
|
$12.48M
|
$10.42M
|
|
Net Cash Flow
|
$-20.22M
|
$-1.75M
|
$6.56M
|
|
PE Ratio
|
|
|
|
|
|
|
